RecruitingNCT07382583
Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
Sponsor
M.D. Anderson Cancer Center
Enrollment
270 participants
Start Date
Feb 12, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
To develop an educational tool to help patients and healthcare professionals make informed decisions about endometrial cancer and available prevention options for it (such as the use of a levonorgestrel-releasing intrauterine system \[LNG-IUS\]).
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria18
- Unaffected women
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must be premenopausal
- Must not have a prior history of EC or complex atypical hyperplasia
- Must provide written, informed consent
- No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member
- Affected women
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must have a prior history of EC or complex atypical hyperplasia
- Must provide written, informed consent
- No physical, psychological, or cognitive impairments that would preclude participation in an interview as determined by the PI or study team member
- Healthcare Providers
- Physicians or advanced practice providers (physician assistants, nurse practitioners) from Family Medicine, Obstetrics \& Gynecology, Internal Medicine, or Endocrinology
- Must be at least 18 years old
- Must read and speak English or Spanish
- Must provide written, informed consent for qualitative interviews
Exclusion Criteria1
- N/A
Interventions
OTHERSurvey using a questionnaire
Patient Preference Utility Assessment and Questionnaires
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07382583
Related Trials
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
NCT072094497 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT0465706879 locations
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT0627649116 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504232 locations